Status:
COMPLETED
Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease?
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Collaborating Sponsors:
Medical Research Council
Conditions:
Chronic Obstructive Pulmonary Disease and Allied Conditions
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to assess usual walking speed (4-metre gait speed) and markers of sarcopenia predict mortality in patients with chronic respiratory disease.
Eligibility Criteria
Inclusion
- All patients with chronic respiratory disease who are able to complete the assessments.
Exclusion
- Significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation).
- Any patient whom the Chief Investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease).
Key Trial Info
Start Date :
December 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
565 Patients enrolled
Trial Details
Trial ID
NCT02261337
Start Date
December 1 2013
End Date
April 1 2022
Last Update
November 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harefield hospital
Harefield, Middlesex, United Kingdom, UB96JH